NMN vs NAD+
Research Comparison

Research Overview

NMN is the precursor; NAD+ is the coenzyme. NMN (nicotinamide mononucleotide) is one nucleotide: nicotinamide, ribose and a phosphate. NAD+ (nicotinamide adenine dinucleotide) is two nucleotides joined by a diphosphate bridge, and it is the form enzymes use: in cell lines it was consumed largely by PARPs and sirtuins (Liu et al., 2018), and CD38 breaks it down as an NADase (Camacho-Pereira et al., 2016).

So is NMN the same as NAD? No. One enzyme step separates them, and that step sets the practical differences in any NMN vs NAD+ comparison: mass, route into the cell, and the questions each can answer. Disguised Alpha supplies NMN as 500MG capsules and NAD+ as buffered lyophilized vials and a 200MG/ML liquid, for laboratory research use only.

Structure and Class

Both are pyridine nucleotides, not peptides. NMN is nicotinamide bonded to beta-D-ribose 5′-phosphate: C11H15N2O8P, 334.22 g/mol (PubChem CID 14180). NAD+ is the same unit joined through a pyrophosphate bond to adenosine monophosphate: C21H27N7O14P2, 663.43 g/mol (PubChem CID 5892). NMN plus adenosine monophosphate (C10H14N5O7P, PubChem CID 6083), less one water, gives the NAD+ formula. The product pages and PubChem agree.

In the salvage pathway, NAMPT, the rate-limiting enzyme, makes NMN from nicotinamide; in mouse primary hepatocytes, NMN overcame the NAD+ deficit caused by the NAMPT inhibitor FK866 but not the one caused by the NMNAT inhibitor gallotannin (Yoshino et al., 2011). NMNAT enzymes then combine NMN with ATP; in human cells, NMNAT3 made NAD+ inside mitochondria from NMN formed in the cytosol (Nikiforov et al., 2011).

Side by Side

Research Context: NMN

How NMN enters cells is the most argued point here. In human cell lines, extracellular NMN was degraded into permeable precursors before entry (Nikiforov et al., 2011). In human cells, the ectoenzyme CD73 converted it to nicotinamide riboside (NR), which supported NAD+ synthesis, while CD38 converted it to nicotinamide and impaired that use (Grozio et al., 2013). Isotope tracing in liver cells and knockout mice showed NMN becoming NR before uptake, with NR kinase 1 required (Ratajczak et al., 2016).

A 2019 study in cells and mice proposed direct import instead: Slc12a8, abundant in mouse small intestine, as a sodium-dependent NMN transporter; knockdown blocked uptake, and its loss lowered NAD+ in jejunum and ileum (Grozio et al., 2019). A critique said the methods and transport data did not support this (Schmidt and Brenner, 2019); the authors replied with proteoliposome and isotope-tracing data (Grozio et al., 2019). Both sides disclosed commercial ties, and the exchange did not settle the question.

In high-fat-diet diabetic mice, intraperitoneal NMN at 500 mg/kg/day for 7 to 10 days restored liver and white adipose NAD+ and normalized glucose tolerance in females (Yoshino et al., 2011).

In male C57BL/6N mice, a 300 mg/kg gavage raised plasma NMN within 2.5 minutes, and over 12 months in drinking water at 100 or 300 mg/kg/day, blood counts, chemistry and urine showed no obvious toxicity (Mills et al., 2016). Isotope tracing in mice found gavaged NMN largely converted to nicotinamide before reaching the circulation, while intravenous delivery brought intact molecules to liver and kidney (Liu et al., 2018).

The human record is small. In a 10-week randomized, placebo-controlled trial in 25 postmenopausal women with prediabetes, NMN raised plasma NMN metabolites and NAD+ in blood mononuclear cells, and clamp-measured muscle insulin sensitivity rose 25 percent, while muscle NAD+ content did not change (Yoshino et al., 2021). The NMN research guide covers the other trials.

NMN is not an approved US drug (Drugs@FDA lists no NMN product). A May 2020 FDA and FTC warning letter called NMN and NAD+ gels sold with COVID-19 claims unapproved new drugs. Late 2022 FDA letters on new dietary ingredient notifications said NMN was excluded from the dietary supplement definition because, apart from unlawful sales, it had not been marketed as a supplement or food before it was authorized for investigation as a new drug (as MIB-626, the agency later said).

On September 29, 2025, answering a citizen petition from the Natural Products Association and the Alliance for Natural Health USA, the FDA reversed course: it dropped the requirement that earlier marketing be lawful, cited evidence of US dietary supplement marketing as early as 2017, and concluded that NMN is not excluded. December 2025 letters set aside the 2022 responses (FDA dockets FDA-2022-S-0023 and FDA-2023-P-0872).

Research Context: NAD+

In mice, isotope tracing put tissue NAD turnover between about 15 minutes and 15 hours, fast in small intestine and spleen and slow in skeletal muscle, with the liver making NAD from tryptophan and exporting nicotinamide (Liu et al., 2018). The NAD+ research guide covers its redox roles.

Added to human cell lines, extracellular NAD was degraded into permeable precursors, which cells rebuilt into cytosolic and mitochondrial NAD (Nikiforov et al., 2011), and in human tumor cells exposed to FK866, extracellular NAD+, NMN or NR each reversed the resulting cell death (Grozio et al., 2013). CD38 degrades both molecules; NMN disappeared quickly in blood from wild-type but not CD38 knockout mice (Camacho-Pereira et al., 2016).

A 2019 pilot followed NAD+ given directly to people: during a 6-hour intravenous infusion in 11 healthy men, 8 given NAD+ and 3 given saline, plasma NAD+ and its metabolites did not change for the first 2 hours, which the authors read as rapid, complete removal from plasma, and urine at 6 hours held more NAD+ and methylnicotinamide (Grant et al., 2019). A company directed by one author co-funded it.

Choosing Between Them for a Research Question

The NAD vs NMN choice follows from where the question sits. Salvage-step questions point to NMN: NAMPT inhibition and rescue, NMNAT activity, CD73 and CD38 processing, NRK1 and Slc12a8 transport; the FK866 and gallotannin contrast above (Yoshino et al., 2011) shows NMN separating NAMPT from NMNAT.

Coenzyme questions point to NAD+: sirtuin, PARP or CD38 enzyme assays, NAD+/NADH redox work and analytical standards. In a cell-free assay NAD+ is the substrate as supplied; added to intact human cell lines, it was degraded outside first (Nikiforov et al., 2011), so report what reached the inside.

Compare the two on moles, not milligrams. In intact cells or animals, measure intracellular NMN and NAD+ and track NR and nicotinamide outside, since both compounds can yield those breakdown products. NMN’s half-life was about 12 hours in culture medium but about 3 minutes in whole blood (Liu et al., 2018).

Handling and Storage

NMN ships as sealed capsules (500MG each, 60 per bottle), listed at 15 to 25°C in the original sealed container, away from moisture and direct light. In solution, NMN stayed 93 to 99 percent intact in drinking water at room temperature for 7 to 10 days (Mills et al., 2016); check stability in your own buffer.

NAD+ ships in glass. Follow the storage instructions on the product page for the size you have, protect it from light and avoid freeze/thaw cycles once a solution is made; for the 200MG/ML liquid, also follow the bottle label. The buffer is not named, so check the pH after reconstitution and prepare working solutions fresh and cold.

For both, use the content measured on the lot certificate for molar work, aliquot stock solutions, and file the certificate from the COA portal with the lot number.

Questions Researchers Ask

Is NMN the same as NAD?

No. NMN is a mononucleotide (334.22 g/mol) and the direct precursor; NAD+ is a dinucleotide (663.43 g/mol) that NMNAT enzymes make from NMN and ATP (Nikiforov et al., 2011). Enzymes use NAD+, not NMN, as the coenzyme.

NAD+ vs NMN: can either enter cells intact?

The evidence is mixed. In human cell lines both were degraded outside the cell first (Nikiforov et al., 2011), while a 2019 study reported direct NMN import through Slc12a8 in mouse intestine (Grozio et al., 2019), which others dispute (Schmidt and Brenner, 2019).

What do CD73 and CD38 do to NMN?

In human cells, CD73 converted NMN to NR, which the cells used for NAD+ synthesis, while CD38 converted it to nicotinamide and impaired that use (Grozio et al., 2013). CD38 also breaks down NAD+ itself (Camacho-Pereira et al., 2016).

Has NAD+ itself been studied in people?

Yes, as research history. In a 2019 infusion pilot in 11 healthy men, 8 given NAD+ and 3 saline controls, plasma NAD+ did not rise for the first 2 hours (Grant et al., 2019).